Treatment of acute cannabinoid overdose with naloxone infusion

References

• United Nations Office on Drugs and Crime (UNODC). World Drug Report; 2017. Available from: https://www.unodc.org/wdr2017/field/WDR17_Fact_sheet.pdf
   Google Scholar
• Azofeifa A, Mattson ME, Schauer G, et al. National estimates of marijuana use and related indicators — national survey on drug use and health, United States, 2002–2014. MMWR Surveill Summ. 2016;65:1–25.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Service Administration. Highlights of the 2011 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. Available from: www.samhsa.gov/data/sites/default/files/DAWN127/DAWN127/sr127-DAWN-highlights.pdf
   Google Scholar
• Wilkinson ST, Yarnell S, Radhakrishnan R, et al. Marijuana legalization: impact on physicians and public health. Annu Rev Med. 2016;67:453–466.
   PubMed Web of Science ®Google Scholar
• Kim HS, Anderson JD, Saghafi O, et al. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015;22:694–699.
   PubMed Web of Science ®Google Scholar
• Wang GS. Pediatric concerns due to expanded cannabis use: unintended consequences of legalization. J Med Toxicol. 2017;13:99–105.
   PubMed Web of Science ®Google Scholar
• Jordan MR, Morrisonponce D. Naloxone. 2017 Jul 1. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun-. Available at: http://www.ncbi.nlm.nih.gov/books/NBK441910
   Google Scholar
• Robledo P, Berrendero F, Ozaita A, et al. Advances in the field of cannabinoid–opioid cross-talk. Addict Biol. 2008;13:213–224.
   PubMed Web of Science ®Google Scholar
• Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neurosci. 2013;248:637–654.
   PubMed Web of Science ®Google Scholar
• ARUP Laboratories. THC Metabolite, Urine, Quantitative. Available at: http://ltd.aruplab.com/Tests/Pub/0090369
   Google Scholar
• Pickel VM, Chan J, Kash TL, et al. Compartment-specific localization of cannabinoid 1 (CB1) and mu opioid receptors in rat nucleus accumbens. Neurosci. 2004;127:101–112.
   PubMedGoogle Scholar
• Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol. 2006;148:387–395.
   PubMed Web of Science ®Google Scholar
• Chen JP, Paredes W, Li J, et al. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl). 1990;102:156–162.
   PubMed Web of Science ®Google Scholar
• Sirohi S, Dighe SV, Madia PA, et al. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity. J Pharmacol Exp Ther. 2009;330:513–519.
   PubMed Web of Science ®Google Scholar
• Justinova Z, Tanda G, Munzar P, et al. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology. 2004;173:186–194.
   PubMed Web of Science ®Google Scholar
• Braida D, Pozzi M, Cavallini R, et al. Conditioned place preference induced by the cannabinoid agonist CP 55, 940: interaction with the opioid system. Neuroscience. 2001;104:923–926.
   PubMed Web of Science ®Google Scholar
• Navarro M, Carrera MR, Fratta W, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci. 2001;21:5344–5350.
   PubMed Web of Science ®Google Scholar
• Braida D, Iosuè S, Pegorini S, et al. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats. Eur J Pharmacol. 2004;506:63–69.
   PubMedGoogle Scholar
• Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology. 2007;32:1391–1403.
   PubMedGoogle Scholar
• Cooper ZD, Haney M. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology. 2010;211:141–148.
   PubMed Web of Science ®Google Scholar
• Haney M, Ramesh D, Glass A, et al. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology. 2015;40:2489–2498.
   PubMed Web of Science ®Google Scholar
• Jones JD, Nolan ML, Daver R, et al. Can naloxone be used to treat synthetic cannabinoid overdose? Biol Psychiatry. 2017;81:e51–e52.
   PubMed Web of Science ®Google Scholar
• Lacroix J, Farrell CA, Gaudreault P, et al. Intoxication orale au cannabis chez sept enfants [Intoxication from accidental ingestion of hashish: analysis of eight cases]. Réanimation Urgences. 1992;1:906–909.
   Google Scholar
• Carstairs SD, Fujinaka MK, Keeney GE, et al. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J Emerg Med. 2011;41:e69–71.
   PubMedGoogle Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–360.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana poisoning. Top Companion Anim Med. 2013;28:8–12.
   PubMed Web of Science ®Google Scholar
• Williams K, Wells RJ, McLean MK. Suspected synthetic cannabinoid toxicosis in a dog. J Vet Emerg Crit Care (San Antonio). 2015;25:739–744.
   PubMed Web of Science ®Google Scholar
• Thompson GR, Rosenkrantz H, Schaeppi UH, et al. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol. 1973;25:363–372.
   PubMed Web of Science ®Google Scholar
• Fitton AG, Pertwee RG. Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol. 1982;75:409–414.
   PubMedGoogle Scholar
• Varvel SA, Bridgen DT, Tao Q, Thomas BF, Martin BR, Lichtman AH. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther. 2005;314:329–337.
   PubMed Web of Science ®Google Scholar
• Singh PP, Das PK. Role of catecholamines in the hypothermic activity of cannabis in albino rats. Psychopharmacology. 1976;50:199–204.
   Google Scholar
• Smiley KA, Karler R, Turkanis SA. Effects of cannabinoids on the perfused rat heart. Res Commun Chem Pathol Pharmacol. 1976;14:659–675.
   PubMedGoogle Scholar
• Borgen LA, Lott GC, Davis WM. Cannabis-induced hypothermia: a dose-effect comparison of crude marihuana extract and synthetic 9 -tetrahydrocannabinol in male and female rats. Res Commun Chem Pathol Pharmacol. 1973;5:621–626.
   Google Scholar
• Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7:149–156.
   PubMedGoogle Scholar
• Manno JE, Manno BR, Kemp PM, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol. 2001;25:538–549.
   PubMed Web of Science ®Google Scholar
• Jemionek JF, Copley CL, Smith ML, et al. Concentration distribution of the marijuana metabolite Delta9-tetrahydrocannabinol-9-carboxylic acid and the cocaine metabolite benzoylecgonine in the department of defense urine drug-testing program. J Anal Toxicol. 2008;32:408–416.
   Google Scholar